ORBIT (Outcome and Retention Rate of Biologic Treatments for Psoriasis): A retrospective observational study on biologic drug survival in daily practice-Reference-Cited by-同舟云学术

ORBIT (Outcome and Retention Rate of Biologic Treatments for Psoriasis): A retrospective observational study on biologic drug survival in daily practice

Published:2016-06 Issue:6 Volume:74 Page:1066-1072
ISSN:0190-9622
Container-title:Journal of the American Academy of Dermatology
language:en
Short-container-title:Journal of the American Academy of Dermatology

Author:

Vilarrasa Eva^ORCID,Notario Jaume,Bordas Xavier,López-Ferrer Anna,Gich Ignasi J.,Puig Lluís

Publisher

Elsevier BV

Subject

Dermatology

Reference15 articles.

1. Adalimumab for the treatment of psoriasis in real life: a retrospective cohort of 119 patients at a single Spanish center;López-Ferrer;Br J Dermatol,2013

2. Spanish evidence-based guidelines on the treatment of moderate-to-severe psoriasis with biologic agents;Puig;Actas Dermosifiliogr,2009

3. Spanish evidence-based guidelines on the treatment of psoriasis with biologic agents, 2013. Part 1: on efficacy and choice of treatment;Puig;Actas Dermosifiliogr,2013

4. Treatment patterns with topicals, traditional systemics and biologics in psoriasis–a Swedish database analysis;Svedbom;J Eur Acad Dermatol Venereol,2015

5. ‘Happy’ drug survival of adalimumab, etanercept and ustekinumab in psoriasis in daily practice care: results from the BioCAPTURE network;van den Reek;Br J Dermatol,2014

Cited by 70 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. VAV1 as a putative therapeutic target in autoimmune and chronic inflammatory diseases;Trends in Immunology;2024-08

2. Drug survival for biologics in psoriasis patients: real world evidence for Greece during the period 2016-2020;Clinical and Experimental Dermatology;2024-07-06

3. A comprehensive overview of psoriatic research over the past 20 years: machine learning-based bibliometric analysis;Frontiers in Immunology;2023-10-26

4. Long lasting response to anti‐tumor necrosis factor α agents in psoriasis: A real life experience;Dermatologic Therapy;2022-11

5. Proportions of Biologic Discontinuation Among Psoriasis Patients With Metabolic Comorbidities;Journal of Psoriasis and Psoriatic Arthritis;2022-09-30